Evaluating Novel formats & Testing Efficacy in Fully Immunosufficient in vivo Models

Time: 11:00 am
day: Focus Day Track A - AM


  • Presenting findings, using a mouse model of multiple myeloma and anti-BCMA/ CD3 bispecific antibody
  • Predicting the risk of immunotoxic events like CRS  in vivo models
  • Addressing mechanisms of acquired resistance to T cell engager therapy